GH
Guardant Health, Inc.
$167.98
-2.79 (-1.63%)
At close · Jul 2
Market Cap
$22.27B
Shares
132,599,929
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$167.98
Open$171.96
Day$166.74–171.99
52W$40.35–172.61
Avg vol 30d3.2M
Short int13.1M · 9.9% float · 6.4d
Short vol31%
Last earningsMay 7, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 7
Equibles Rating
blended score · not investment advice
Overall
Neutral
Technical · trend & momentum
Buy
◦
50 / 200-day cross
no cross
+
Price vs 200-day avg
+72% above
+
Price vs 50-day avg
+44% above
−
RSI (14)
77 · overbought
+
MACD trend
positive
+
52-week position
96% · near high
Sentiment · smart money
Neutral
◦
Trend (MA cross)
50d $117 › 200d $98 — 50d above 200d
−
Institutional flow
4 of 488 funds reported for Jun 30 · net -110 sh shares
−
Insider flow
Net -$52.0M over 90 days · 92% sells
+
Short interest
9.87% of float · ▼ -0.9% MoM · 6.4 days cover
◦
Volume signal
Volume near normal
+
Institution breadth
488 holders — near 3-yr high, broad support
Fundamentals
Weak
+
Revenue growth
+33% Y/Y
◦
EPS growth
+7% Y/Y
−
Free cash flow
$-233.1M
−
Balance sheet
net debt $1.1B
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Aug 6, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Guidance & track record
Latest guidance
· from the 8-K filed May 7, 2026
full year 2026
Total revenue
Initiated
$1.3B – $1.32B
prior FY $982.02M
midpoint +33.4% Y/Y
Non-GAAP gross margin
Non-GAAP
Initiated
64% – 65%
Total non-GAAP operating expenses
Non-GAAP
Initiated
$1.05B – $1.07B
2026
Oncology revenue growth
Initiated
28% – 29%
Oncology volume growth
Initiated
at least 35%
Screening revenue
Initiated
$186M – $198M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
+72% above
Bullish
Price vs 50-day avg
+44% above
Bullish
RSI (14)
77 · overbought
Bearish
MACD trend
positive
Bullish
52-week position
96% · near high
Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $117 › 200d $98 — 50d above 200d
Institutional flow
Distributing
4 of 488 funds reported for Jun 30 · net -110 sh shares
Insider flow
Distributing
Net -$52.0M over 90 days · 92% sells
Short interest
Falling
9.87% of float · ▼ -0.9% MoM · 6.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
488 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $40
Now $168 · 96%
52-wk high $173
vs 200-day avg +72%
vs 50-day avg +44%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA loss non-GAAP | -$58.9M | Q1 2026 | — |
| Non-GAAP gross margin non-GAAP | 66% | Q1 2026 | — |
|
|
|||
| Oncology tests | 86,000 | Q1 2026 | — |
|
|
|||
| Shield screening tests | 44,000 | Q1 2026 | — |
|
|
|||
| Adjusted EBITDA non-GAAP | -$64.9M | Q4 2025 | — |
| Free cash flow | -$233M | Full Year FY2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GH
this stock
Guardant Health, Inc.
|
$22.27B | +64.5% | +32.9% | — | 9.9% |
|
TMO
Thermo Fisher Scientific Inc.
|
$194.52B | -9.6% | +0.4% | 28.8 | 1.2% |
|
DHR
Danaher Corp /De/
|
$140.09B | -13.4% | +8.5% | 38.2 | 1.6% |
|
IDXX
Idexx Laboratories Inc /De
|
$44.00B | -17.5% | +10.4% | 41.0 | 2.7% |
|
NTRA
Natera, Inc.
|
$40.00B | +21.9% | -2.8% | — | 3.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GH | +17.5% | +32.2% | +54.5% | +12.0% | +64.5% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | +16.1% | +33.5% | +46.5% | +12.2% | +55.2% |